Overall, our data demonstrate that the proposed adenovirus encoding IL-7 effectively reduces tumor burden and stimulates the presence of effector immune cells, including CD4+, CD8+, NKT, and NK cells, marking it as a promising therapeutic option for advanced and metastatic RCC and suitable for combination with ICIs such as anti-PD-1 or anti-PD-L1. Here, IL7 is linked to neoplasm.